Compare · ACON vs ILMN
ACON vs ILMN
Side-by-side comparison of Aclarion Inc. (ACON) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACON and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.38B, about 5033.6x ACON ($5.6M).
- Over the past year, ACON is down 68.9% and ILMN is up 98.4% - ILMN leads by 167.2 points.
- ILMN has been more active in the news (8 items in the past 4 weeks vs 4 for ACON).
- ILMN has more recent analyst coverage (25 ratings vs 0 for ACON).
- Company
- Aclarion Inc.
- Illumina Inc.
- Price
- $2.26-3.83%
- $188.04-3.07%
- Market cap
- $5.6M
- $28.38B
- 1M return
- -22.34%
- -2.94%
- 1Y return
- -68.87%
- +98.35%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2000
- News (4w)
- 4
- 8
- Recent ratings
- 0
- 25
Aclarion Inc.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest ACON
- SEC Form 10-Q filed by Aclarion Inc.
- Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology
- Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
- Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice
- SEC Form S-8 filed by Aclarion Inc.
- Aclarion Announces Texas Spine Care Center as New CLARITY Site
- Chief Strategy Officer Bond Ryan was granted 55,000 shares (SEC Form 4)
- Executive Chairman Thramann Jeffrey John was granted 100,000 shares (SEC Form 4)
- Chief Financial Officer Gould Gregory A was granted 50,000 shares (SEC Form 4)
- Director Sequira Amanda Mae was granted 20,000 shares (SEC Form 4)
Latest ILMN
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $123,000 worth of shares (615 units at $200.00), decreasing direct ownership by 3% to 20,338 units (SEC Form 4)
- SEC Form 10-Q filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
- SEC Form 3 filed by new insider Sullivan Michael C
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026